DEPO-TESTOSTERONE INJ 100MG/ML SOLUTION

Riik: Kanada

keel: inglise

Allikas: Health Canada

Osta kohe

Toote omadused Toote omadused (SPC)
12-07-2018

Toimeaine:

TESTOSTERONE CYPIONATE

Saadav alates:

PFIZER CANADA ULC

ATC kood:

G03BA03

INN (Rahvusvaheline Nimetus):

TESTOSTERONE

Annus:

100MG

Ravimvorm:

SOLUTION

Koostis:

TESTOSTERONE CYPIONATE 100MG

Manustamisviis:

INTRAMUSCULAR

Ühikuid pakis:

10ML

Retsepti tüüp:

Schedule G (CDSA IV)

Terapeutiline ala:

ANDROGENS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0106401001; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2001-06-04

Toote omadused

                                _ _
_DEPO-TESTOSTERONE Product Monograph _
_ _
_Page 1 of 20_
PRODUCT MONOGRAPH
DEPO-TESTOSTERONE
testosterone cypionate injection
100 mg/mL sterile solution
USP
Androgens
Pfizer Canada Inc.
17, 300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5
Date of Revision:
July 12, 2018
Submission Control No: 217239
©
Pfizer Canada Inc., 2018
_ _
_DEPO-TESTOSTERONE Product Monograph _
_Page 2 of 20 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................8
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE
................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
............................................................12
STORAGE AND STABILITY
..........................................................................................13
SPECIAL HANDLING INSTRUCTIONS
.......................................................................14
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................14
PART II: SCIENTIFIC INFORMATION
...............................................................................15
PHARMACEUTICAL INFO
                                
                                Lugege kogu dokumenti
                                
                            

Dokumendid teistes keeltes

Toote omadused Toote omadused prantsuse 12-07-2018